AstraZeneca licenses novel antidepressant compounds discovered by Mayo Clinic, Virginia Tech collaboration
MetadataShow full item record
AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds.
- Virginia Tech News